The estimated Net Worth of Michael Severino is at least $70.7 Milhão dollars as of 23 May 2022. Michael Severino owns over 79,801 units of Abbvie Inc stock worth over $45,126,199 and over the last 10 years he sold ABBV stock worth over $16,103,339. In addition, he makes $9,508,450 as President e Vice Chairman at Abbvie Inc.
Michael has made over 7 trades of the Abbvie Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 79,801 units of ABBV stock worth $8,697,511 on 23 May 2022.
The largest trade he's ever made was exercising 300,000 units of Abbvie Inc stock on 6 May 2022 worth over $17,037,000. On average, Michael trades about 23,399 units every 52 days since 2014. As of 23 May 2022 he still owns at least 231,904 units of Abbvie Inc stock.
You can see the complete history of Michael Severino stock trades at the bottom of the page.
Dr. Michael E. Severino, M.D., is President, Vice Chairman of the Company. Dr. Severino is AbbVie's Executive Vice President, Research and Development and Chief Scientific Officer. Dr. Severino served at Amgen Inc. as Senior Vice President, Global Development and Corporate Chief Medical Officer from 2012 to 2014, as Vice President, Global Development from 2010 to 2012 and as Vice President, Therapeutic Area Head, General Medicine and Inflammation Global Clinical Development from 2007 to 2012. He joined AbbVie in 2014.
As the President e Vice Chairman of Abbvie Inc, the total compensation of Michael Severino at Abbvie Inc is $9,508,450. There are 3 executives at Abbvie Inc getting paid more, with Richard Gonzalez having the highest compensation of $21,610,600.
Michael Severino is 54, he's been the President e Vice Chairman of Abbvie Inc since 2018. There are 21 older and 10 younger executives at Abbvie Inc. The oldest executive at Abbvie Inc is Edward Liddy, 73, who is the Independent Director.
Michael's mailing address filed with the SEC is RADNOR CORPORATE CENTER, BUILDING ONE,, SUITE 200, 100 MATSONFORD ROAD, RADNOR, PA, 19087.
Over the last 12 years, insiders at Abbvie Inc have traded over $324,915,370 worth of Abbvie Inc stock and bought 214,015 units worth $14,446,494 . The most active insiders traders include Richard A Gonzalez, Frederick H Waddell, eGlenn F Tilton. On average, Abbvie Inc executives and independent directors trade stock every 22 days with the average trade being worth of $7,529,855. The most recent stock trade was executed by Richard A Gonzalez on 5 August 2024, trading 66,500 units of ABBV stock currently worth $12,403,580.
AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.
Abbvie Inc executives and other stock owners filed with the SEC include: